Re-education of myeloid immune cells to reduce regulatory T cell expansion and impede breast cancer progression
Vidana Gamage, Hashni Epa
This item's files can only be accessed by the System Administrators group.
Permalink
https://hdl.handle.net/2142/127425
Description
Title
Re-education of myeloid immune cells to reduce regulatory T cell expansion and impede breast cancer progression
Author(s)
Vidana Gamage, Hashni Epa
Issue Date
2024-08-02
Director of Research (if dissertation) or Advisor (if thesis)
Nelson, Erik R
Doctoral Committee Chair(s)
Nelson, Erik R
Committee Member(s)
Ridlon, Jason M
Hergenrother, Paul J
Raetzman, Lori T
Department of Study
Molecular & Integrative Physl
Discipline
Molecular & Integrative Physi
Degree Granting Institution
University of Illinois at Urbana-Champaign
Degree Name
Ph.D.
Degree Level
Dissertation
Keyword(s)
Cholesterol
Dshn-ome
Nuclear Receptor
Small Heterodimer Partner
Treg.
Language
eng
Abstract
Although survival from breast cancer has dramatically increased, many will develop recurrent, metastatic disease. Unfortunately, the survival for this stage of the disease remains very low. Stimulating patients own immune systems against cancer cells has shown incredible curative potential in certain types of cancers and patients such as melanoma. However, immune checkpoint blockade (ICB) which works through T cells has had limited efficacy in breast cancer. Therefore, there is considerable interest in alternate strategies to promote an anti-cancer immune response. Infiltration of immune-suppressive regulatory T cells (Treg) to the tumor microenvironment (TME) is associated with resistance to ICB. Tregs are a subset of CD4+ T cells known to be highly immune suppressive and associated with poor therapeutic response. Interestingly, within human breast tumors, NR0B2, a protein involved in cholesterol homeostasis, is inversely associated with FOXP3, a marker of Tregs. Myeloid intrinsic NR0B2 serves to decrease many aspects of the NLRP3 inflammasome, ultimately resulting in decreased IL1β; IL1β driving Treg expansion. Importantly, mice lacking NR0B2 exhibit accelerated tumor growth. Furthermore, we have developed NR0B2 as a potential therapeutic target. Small molecule agonists, including one developed here, reduced Treg expansion, reduced metastatic growth, and improved the efficacy of ICB. Together these findings demonstrate NR0B2 as a target to ‘re-educate’ myeloid immune cells and its potential utility in enhancing ICB. This work identifies NR0B2 as a target to re-educate myeloid immune cells and a novel ligand with significant anti-tumor efficacy in preclinical models.
Use this login method if you
don't
have an
@illinois.edu
email address.
(Oops, I do have one)
IDEALS migrated to a new platform on June 23, 2022. If you created
your account prior to this date, you will have to reset your password
using the forgot-password link below.
